−Removed: SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
+Added: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During January 2020 and 2019, our Board of Directors authorized share repurchase programs for up to $4 billion ($2 billion for each authorization) of our outstanding common stock.
−Removed: In response to the risks the COVID-19
−Removed: pandemic presents to our business, during March 2020, we announced the suspension of our share repurchase programs and expect to evaluate the resumption of the programs at a future date.
−Removed: There were no share repurchases of our outstanding common stock during the third quarter of 2020.
−Removed: At September 30, 2020, we had $2.800 billion of repurchase authorization available under the January 2019 and 2020 authorizations.
−Removed: In response to the COVID-19
−Removed: pandemic concerns, the Company suspended its quarterly dividend program for the second and third quarters of 2020.
−Removed: The Company expects to evaluate resumption of the program at a future date.
−Removed: Any other future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors.
+Added: During February 2021, our Board of Directors authorized an additional $6 billion for repurchases of our outstanding common stock.
+Added: During the quarter ended March 31, 2021, we repurchased 8,476,736 shares of our common stock at an average price of $180.11 per share through market purchases pursuant to the $2.0 billion share repurchase program authorized during January 2019 (which was completed during the first quarter of 2021) and the January 2020 authorization.
+Added: At March 31, 2021, we had $7.274 billion of repurchase authorization available under the January 2020 and February 2021 authorizations.
+Added: The following table provides certain information with respect to our repurchases of common stock from January 1, 2021 through March 31, 2021 (dollars in millions, except per share amounts).
+Added: Average Price
+Added: Paid per Share
+Added: Dollar Value of
+Added: Under Publicly
+Added: January 1, 2021 through January 31, 2021
+Added: February 1, 2021 through February 28, 2021
+Added: March 1, 2021 through March 31, 2021
+Added: Total for first quarter 2021
+Added: On April 21, 2021, our Board of Directors declared a quarterly dividend of $0.48 per share on our common stock payable on June 30, 2021 to stockholders of record at the close of business on June 16, 2021.
+Added: Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors.
Our ability to declare future dividends may also from time to time be limited by the terms of our debt agreements.
(a) List of Exhibits:
−Removed: List of Subsidiary Guarantors (filed as Exhibit 22 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (File No.
+Added: HCA Healthcare, Inc.
+Added: 2021 Senior Officer Performance Excellence Program (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 9, 2021 (File No.
001-11239), and incorporated herein by reference).*
+Added: List of Subsidiary Guarantors and Pledged Securities.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
3 unchanged sentences
The following financial information from our quarterly report on Form 10-Q
−Removed: for the quarters and nine months ended September 30, 2020 and 2019, filed with the SEC on October 29, 2020, formatted in Inline Extensible Business Reporting Language:
−Removed: (i) the condensed consolidated balance sheets at September 30, 2020 and December 31, 2019, (ii) the condensed consolidated income statements for the quarters and nine months ended September 30, 2020 and 2019, (iii) the condensed consolidated comprehensive income statements for the quarters and nine months ended September 30, 2020 and 2019, (iv) the condensed consolidated statements of stockholders’ equity (deficit) for the quarters and nine months ended September 30, 2020 and 2019, (v) the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 and (vi) the notes to condensed consolidated financial statements.
+Added: for the quarter ended March 31, 2021 filed with the SEC on April 30, 2021, formatted in Inline Extensible Business Reporting Language:
+Added: (i) the condensed consolidated balance sheets at March 31, 2021 and December 31, 2020, (ii) the condensed consolidated income statements for the quarters ended March 31, 2021 and 2020, (iii) the condensed consolidated comprehensive income statements for the quarters ended March 31, 2021 and 2020, (iv) the condensed consolidated statements of stockholders’ equity (deficit) for the quarters ended March 31, 2021 and 2020, (v) the condensed consolidated statements of cash flows for the quarters ended March 31, 2021 and 2020 and (vi) the notes to condensed consolidated financial statements.
The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
The cover page from the Company’s Quarterly Report on Form 10-Q
−Removed: for the quarter ended September 30, 2020, formatted in Inline XBRL (included in Exhibit 101).
+Added: for the quarter ended March 31, 2021, formatted in Inline XBRL (included in Exhibit 101).
+Added: Management compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
2 unchanged sentences
Executive Vice President and Chief Financial Officer
−Removed: October 29, 2020
+Added: April 30, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.